Wells Fargo & Company Begins Coverage on Merus (NASDAQ:MRUS)

Equities research analysts at Wells Fargo & Company initiated coverage on shares of Merus (NASDAQ:MRUS) in a research report issued on Friday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $91.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 119.07% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. UBS Group began coverage on shares of Merus in a research note on Thursday, October 24th. They issued a “buy” rating and a $72.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and issued a $109.00 price target (down from $111.00) on shares of Merus in a research note on Tuesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 9th. Finally, Citigroup upped their price target on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $86.08.

Merus Stock Down 0.3 %

MRUS opened at $41.54 on Friday. Merus has a 12-month low of $35.67 and a 12-month high of $61.61. The firm has a market capitalization of $2.84 billion, a P/E ratio of -10.52 and a beta of 1.11. The stock has a fifty day moving average of $42.24 and a 200-day moving average of $47.86.

Institutional Investors Weigh In On Merus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Avior Wealth Management LLC acquired a new stake in shares of Merus in the fourth quarter valued at about $76,000. nVerses Capital LLC grew its position in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares during the last quarter. US Bancorp DE acquired a new stake in shares of Merus in the third quarter valued at about $103,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the last quarter. Finally, MML Investors Services LLC acquired a new stake in shares of Merus in the third quarter valued at about $206,000. 96.14% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.